Head-To-Head Comparison: Elevation Oncology (NASDAQ:ELEV) and Bio-Techne (NASDAQ:TECH)

Elevation Oncology (NASDAQ:ELEV) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Insider & Institutional Ownership

83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 98.9% of Bio-Techne shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by insiders. Comparatively, 3.9% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Elevation Oncology and Bio-Techne’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elevation Oncology	N/A	-59.73%	-40.05%
Bio-Techne	12.86%	12.76%	9.59%

Volatility & Risk

Elevation Oncology has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Elevation Oncology and Bio-Techne, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevation Oncology	0	0	6	0	3.00
Bio-Techne	0	3	5	0	2.63

Elevation Oncology presently has a consensus price target of $7.20, indicating a potential upside of 855.16%. Bio-Techne has a consensus price target of $82.00, indicating a potential upside of 9.06%. Given Elevation Oncology’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Elevation Oncology is more favorable than Bio-Techne.

Earnings & Valuation

This table compares Elevation Oncology and Bio-Techne”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevation Oncology	N/A	N/A	-$45.70 million	($0.82)	-0.92
Bio-Techne	$1.17 billion	10.20	$168.10 million	$0.94	79.99

Bio-Techne has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Elevation Oncology on 8 of the 13 factors compared between the two stocks.

About Elevation Oncology

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.